Blog
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Accelerating ATMP and CGT: The importance of Regulatory CMC expertise in efficient biologics development
Discover how dedicated Regulatory CMC expertise benefits biologics development, ensuring compliance and efficiency, especially for innovative therapies like ATMPs and CGTs.
-
Why using COAs and DHTs together is the future of clinical research
Though both COAs and DHTs are tools used to evaluate a treatment’s impact, they often exist in separate spheres, rarely integrated. We argue that combining these two approaches in the same study can help researchers gather better data and improve the likelihood of regulatory approval.
-
Enhancing diversity in clinical trials
To fully assess the efficacy and safety of a therapeutic indication, clinical trials must evaluate populations that are representative of the treatment population, as different people may experience the same disease differently.
-
Unlocking the value of transparent healthcare data
In this blog, we'll explore how transparency in healthcare data can unlock its full potential. Discover why transparency matters and how Symphony Health’s approach ensures you get the most accurate, actionable insights.
-
Digital health: Why evaluating human factors is essential
With the rapidly evolving technology, digital health is transforming healthcare, emerging as a promising solution to reduce rising healthcare costs and improve patient care.
-
Digital health: Managing cybersecurity risks
When developing a new digital health device, as well as maintaining an existing device, securing the device from cybersecurity attacks is critical.
-
_drug_pill_thumbnail.jpg?crop=yes&w=210&h=209&itok=OnEdqPdO "pill_drug_reduction_thumbnail")
Navigating the impacts of the Inflation Reduction Act (IRA): Strategic considerations for pharma
Explore the Inflation Reduction Act’s key points of impact on pharmaceutical companies and considerations to strategically evolve with the coming changes.
-
Medicare Part D Price Negotiations update – Widespread impact on the industry
The Inflation Reduction Act (IRA) and resulting Medicare Part D price negotiations promise widespread impact on the industry. For the first time in history, the government is empowered to negotiate drug pricing directly with manufacturers.
-
Utilising connected sensors to power diverse and equitable clinical trials
Our publication in Nature npj Digital Medicine outlines current evidence and a solution framework for diversity in research using digital health technologies.
-
Outcome Measures: Driving forward patient-centered clinical trials
ICON’s Outcome Measures service aims to drive forward patient-centered treatments while also helping sponsors increase the likelihood of regulatory approval.
-
Enabling a new way to select fit-for-purpose COAs to simplify clinical protocols
While digital health technologies are one piece of the clinical protocol puzzle, holistic protocol design requires more breadth.
-
Enhancing diversity in clinical trials with AI and human expertise
Explore how AI-enabled insights and data-driven site selection can play a key part in a multifaceted approach to diversity in clinical trials and benefit equity in healthcare by extension.
-
The rise of precision outcome measures
Precision outcome measures are the means by which to evaluate a meaningful change on the exact outcome of interest, regardless of tool or instrument.
-
Understanding China's 2024 NRDL: Key changes and their impact
This blog provides an overview of the NRDL’s history, highlights the key changes for 2024, and discusses the potential impact on both local and international pharmaceutical industries.
-
Unlocking quality in machine translation: The impact of ISO 18587 certification on clinical research
ISO 18587 certification helps ensure consistency and quality in the post-editing process, fostering trust and confidence in machine-translated content across various industries and applications.
-
The race to develop combination vaccines – and the importance of indirect effects
A development race is currently underway in the field of combination vaccines, with a number of influential pharmaceutical and biotech companies pursuing combination vaccines targeting influenza and COVID-19.
-
Tested, tried and true: Why digital biomarkers are the AI & ML strategy pharma should prioritise
Rather than chasing generative AI, pharma executives can focus their AI & machine learning (ML) strategies for drug development on investing in and deploying connected sensors to reduce costs & improve patient outcomes.
-
Outcome measures: Driving precision health strategies forward
ICON has been speaking, collaborating, and building with top pharma throughout the year to help them develop better drugs, faster, for patients. Here are a few observations from this year.
-
Digital endpoints widely adopted in pharmaceutical and biotech-sponsored clinical trials
Over 130 pharma and biotech organizations have relied on AI-powered digital biomarkers and sensor-derived clinical outcome assessments (COAs) to capture patient-centered endpoints.
-
The impact of AI on the evolution of machine translation
From its nascent stages to the sophisticated systems we employ today, machine translation has become an indispensable efficiency generating tool.